Fine comparision of the efficacy and safety between GB242 and infliximab in patients with active moderate to severe rheumatoid arthritis: a randomized, double-blind, phase III study

MLA

Y Wang, et al. Fine Comparision of the Efficacy and Safety between GB242 and Infliximab in Patients with Active Moderate to Severe Rheumatoid Arthritis: A Randomized, Double-Blind, Phase III Study. May 2021. EBSCOhost, https://doi.org/10.21203/rs.3.rs-436813/v1.

APA

Y Wang, Yanying Liu, Zhanyun Da, Ling Wang, Fuai Lu, Hua Wei, Xiaowei Gong, Jian Wu, Zhenyu Jiang, Li Luo, Niansheng Yang, Lie Dai, Shengyun Liu, Yingxue Cathy Liu, Kexia Chai, Linjie Chen, Ju Liu, Lijun Wu, Xiumei Liu, … Hui Song. (2021). Fine comparision of the efficacy and safety between GB242 and infliximab in patients with active moderate to severe rheumatoid arthritis: a randomized, double-blind, phase III study. https://doi.org/10.21203/rs.3.rs-436813/v1

Chicago

Y Wang, Yanying Liu, Zhanyun Da, Ling Wang, Fuai Lu, Hua Wei, Xiaowei Gong, et al. 2021. “Fine Comparision of the Efficacy and Safety between GB242 and Infliximab in Patients with Active Moderate to Severe Rheumatoid Arthritis: A Randomized, Double-Blind, Phase III Study,” May. doi:10.21203/rs.3.rs-436813/v1.